Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.
Study is the first to demonstrate cross-protective immunity by vaccines
Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.
The COVID-19 pandemic has highlighted the importance of preventive health behaviors. While public health experts agree that we won’t have an approved and widely available COVID-19 vaccine for some time, there are steps that people can take to stay healthy and safe. That includes getting the seasonal flu vaccine. So today we’re announcing new steps as part of our continued work to help support vaccine efforts.